Understanding Cancer Patients' Preferences for Genetic Information Before Exome Analysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how cancer patients prefer to receive genetic information prior to undergoing theranostic exome analysis. It involves observing patient-physician communication during consultations and conducting interviews with patients to gather insights on their preferences. The study aims to enhance understanding of how information is conveyed and comprehended, ensuring that patients are well-informed about their treatment options. Participants will be drawn from the EXOMA2 patient file at Dijon University Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient identified for inclusion in the EXOMA 2 study (exome analysis request)
* Available to receive different types of information
* Fluent in French
* No prior oncogenetic consultation
* Having been informed of the objectives of the study and having given written non-objection to participate in the INFOGene study
* Authorizing audio recording of consultations and interviews

Exclusion Criteria:

* Patient who refused to participate in the EXOMA2 study (for phase 3 patients only)
* Has a psychiatric, cognitive or neurological disorder that makes participation impossible
* Working in the field of genetics

Where it's running

• Centre Georges-François Leclerc
  Dijon, France Recruiting
• CHU François Mitterand
  Dijon, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting who responds to anti-PD-1/PD-L1 therapy using blood extracellular vesicle tests

  This study tests whether immune biomarkers found in blood extracellular vesicles can predict who with NSCLC or unresectable melanoma will respond to anti-PD-1/PD-L1 therapies.

  Recruiting at 2 sites Centre Georges Francois Leclerc · Besançon and 4 other locations · NCT07376512

• Ultra-rapid testing for BRCA1/2 mutations in breast cancer patients

  This study tests a fast BRCA1/2 mutation screening for breast cancer patients to see if it can reduce their waiting time for results and help ease their anxiety.

  Recruiting at 2 sites Centre Georges Francois Leclerc · Dijon and 1 other locations · NCT06111417

• Evaluating FOLFIRINOX treatment for advanced pancreatic cancer

  This study is testing if a specific chemotherapy called FOLFIRINOX can help people with advanced pancreatic cancer feel better and live longer compared to other treatments.

  Recruiting Phase 2 Centre Georges Francois Leclerc · Dijon · NCT05988814

• Evaluating a new treatment for advanced lung cancer with low PD-L1 levels

  This study is testing a new treatment combining mirdametinib and chemotherapy for people with advanced lung cancer and low PD-L1 levels to see if it helps them.

  Recruiting Phase 1/2 Centre Georges Francois Leclerc · Dijon, Burgundy · NCT05937906

• Using a non-magnetic screen to guide breathing during MRI-guided radiotherapy for mobile cancerous lesions

  This study is testing if using a special non-magnetic screen during MRI-guided radiotherapy can help patients with mobile cancerous lesions breathe better and improve their treatment experience.

  Recruiting Centre Georges Francois Leclerc · Dijon, Côte d'Or · NCT05783908

• Monitoring immune responses in breast cancer patients during treatment

  This study is testing how different treatments for breast cancer affect the immune system by collecting blood samples from women during their therapy.

  Recruiting Centre Georges Francois Leclerc · Besançon and 1 other locations · NCT04925856

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.